Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.98% is 41% above its 5-year average of -76.85%, near the high end of its 5-year range (-153.44%–-31.09%).
41.22% above its 12-month average of -76.52%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.93%.
RETURN ON ASSETS (ROA)
-44.98%
RETURN ON ASSETS (ROA) AVG TTM
-76.52%
RETURN ON ASSETS (ROA) AVG 3Y
-94.59%
RETURN ON ASSETS (ROA) AVG 5Y
-76.85%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.22%
CURRENT VS 3Y AVG
+52.45%
CURRENT VS 5Y AVG
+41.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-42.91%
vs the sector median at left
Immunome, Inc.
Market Cap
$1.90B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$1.90B
Return on Assets (ROA)
-37.11%
TTM Avg
4.34%
3Y Avg
-11.90%
5Y Avg
4.27%
Market Cap
$1.91B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
Market Cap
$1.85B
Return on Assets (ROA)
1.78%
TTM Avg
2.10%
3Y Avg
3.84%
5Y Avg
3.40%
Market Cap
$1.84B
Return on Assets (ROA)
-25.92%
TTM Avg
12.70%
3Y Avg
-8.51%
5Y Avg
-21.36%
Market Cap
$1.84B
Return on Assets (ROA)
-24.34%
TTM Avg
-44.90%
3Y Avg
-10.89%
5Y Avg
-12.22%
Market Cap
$1.96B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
Market Cap
$1.83B
Return on Assets (ROA)
-6.55%
TTM Avg
-5.28%
3Y Avg
-5.65%
5Y Avg
-2.06%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.90B | -44.98% | -76.52% | -94.59% | -76.85% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | -37.11% | 4.34% | -11.90% | 4.27% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | -11.05% | -19.34% | -25.88% | -26.23% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 1.78% | 2.10% | 3.84% | 3.40% |
| Novavax, Inc. (NVAX)vs › | $1.84B | -25.92% | 12.70% | -8.51% | -21.36% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -24.34% | -44.90% | -10.89% | -12.22% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | -11.00% | -5.98% | -9.46% | -10.43% |
| Azenta, Inc. (AZTA)vs › | $1.83B | -6.55% | -5.28% | -5.65% | -2.06% |
| Xencor, Inc. (XNCR)vs › | $1.84B | -22.53% | -17.47% | -13.86% | -9.24% |
ROA
-45.0%
ROE
-48.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -31.09% |
| 2024-12-31 | -121.95% |
| 2023-12-31 | -71.90% |
| 2022-12-31 | -153.44% |
| 2021-12-31 | -42.66% |
| 2020-12-31 | -40.06% |
| 2019-12-31 | -208.50% |
| 2018-12-31 | -176.37% |
